ArticleJournal of arrhythmia2026
The Evolving Role of Ivabradine for Focal Atrial Tachycardia: A Systematic Review.
Article in Journal of arrhythmia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Ivabradine was initially introduced for heart failure and coronary artery disease patients, with its interesting feature of heart rate reduction without reducing heart contractility or blood pressure. In recent years, however, the use of ivabradine evolved for arrhythmia, including for focal atrial tachycardia (FAT). This systematic review aims to evaluate all the existing evidence on ivabradine for focal atrial tachycardia and synthesize information on its use, including efficacy and safety. Methods: A comprehensive literature search was conducted in three large databases: PubMed, ScienceDirect, and Scopus, following the PRISMA guidelines, using the search terms of: (ivabradine) AND (atrial tachycardia). Studies were included if they reported the use of Ivabradine for FAT in humans. Studies on atrial tachycardia outside of focal mechanisms or any other arrhythmias were excluded. Results: The search strategy resulted in 375 articles: 63 from PubMed, 262 from ScienceDirect, and 50 from Scopus, which subsequently resulted in 19 articles included for final review after a meticulous filtering process. The included studies were 11 case reports, 4 case series, and 4 observational studies discussing the outcome of ivabradine for focal atrial tachycardia. Conclusion: Evidence from small cohorts and case reports suggests promising outcomes and a good safety profile of ivabradine for FAT, but larger, well-designed and more robust studies are needed. Recognizing an automaticity-driven FAT is key to considering ivabradine, especially when FAT persists despite cardioversion or standard therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.